A prodrug that consists of a FAP-specific peptide coupled to a cytotoxic analog of thapsigargin, induced stromal cell death in prostate and breast tumor xenografts and decreased tumor volumes by ~70% (61). This evidence concerns the gene FAP and neoplasm.